title: [The complex energy correction of chronic brain ischemia].
abstract: Considerable disturbance of all quality of life domains that worsens social adaptation and daily living and results in an asthenic-neurotic syndrome, along with neurologic and mnestic-intellectual disturbances, was revealed in patients with chronic brain ischemia (stages I, II, III). Based on the results of the double blind placebo-controlled trial, the high clinical efficacy of cytoflavin in patients with chronic brain ischemia has been shown. The treatment with cytoflavin decreases the severity of subjective symptoms and complaints thus increasing the working ability of patients, improves balance and gait, decreases the severity of asthenic and neurotic syndromes, improves cognitive and memory functions (information storage, reasoning and attention), positively effects on quality of sleep and all aspects of quality of life, in particular, on physical activity, self-rating of health and viability as well as social activity, mental health and emotional lability.
authors.forename: Z A
authors.initials: ZA
authors.lastname: Suslina
authors.forename: S A
authors.initials: SA
authors.lastname: Rumiantseva
authors.forename: M M
authors.initials: MM
authors.lastname: Tanashian
authors.forename: A A
authors.initials: AA
authors.lastname: Skoromets
authors.forename: E G
authors.initials: EG
authors.lastname: Klocheva
authors.forename: A I
authors.initials: AI
authors.lastname: Fedin
authors.forename: A L
authors.initials: AL
authors.lastname: Kovalenko
authors.forename: E V
authors.initials: EV
authors.lastname: Silina
authors.forename: I I
authors.initials: II
authors.lastname: Sholomov
mesh_terms: D000975:Antioxidants / Q000627:therapeutic use*; D002545:Brain Ischemia / Q000188:drug therapy* / Q000503:physiopathology; D003071:Cognition / Q000187:drug effects; D004338:Drug Combinations; D005260:Female; D005486:Flavin Mononucleotide / Q000627:therapeutic use*; D006801:Humans; D007290:Inosine Diphosphate / Q000627:therapeutic use*; D008297:Male; D009536:Niacinamide / Q000627:therapeutic use*; D013386:Succinates / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D000975:Antioxidants; D004338:Drug Combinations; D013386:Succinates; C507879:cytoflavin; D009536:Niacinamide; D005486:Flavin Mononucleotide; D007290:Inosine Diphosphate